A Look Back at ICLE 2025

ICLE 2025 in Munich brought together delegates from 30+ countries, Nobel Laureate Drew Weissman, Breakthrough Prize winner Carl June, and leading voices in the field. Ideas sparked, connections formed, and momentum grew.

Between packed sessions and lively discussions, the energy was undeniable. The work continues, and so does the conversation.

Featured Speakers

Exhibitors & Sponsors 2025

The ICLE Advantage - Enhance Your Future

Embark on a journey at the forefront of scientific exploration, where groundbreaking topics take center stage. This is the exclusive platform where leading minds unveil the latest breakthroughs, sharing insights that bridge the gap from research to clinical practice. Immerse yourself in invaluable discussions with top-notch experts in lymphocyte engineering therapies, gaining a firsthand understanding of the challenges and triumphs in the field.

REVOLUTIONARY TOPIC

The only international conference focusing specifically on research and clinical translation of gene therapy, cell therapy, genome engineering, and immunotherapy.

LATEST BREAKTHROUGHS

Learn what is done to translate the lymphocyte engineering research to clinical practice and how your colleagues overcome their challenges.

TOP-NOTCH EXPERTS

Hear from renown leaders, sharing invaluable insights on lymphocyte engineering therapies and discuss the latest findings and trends.

ESTABLISH COLLABORATIONS

ICLE's international community of scientists at the forefront of translational medicine is the place to be to create new successful partnerships.

AMPLIFIED EXPOSURE

Make your work visible, receive feedback, discuss your results with colleagues and experts from all over the world, and find future collaborators.

GREAT LOCATION

Home to the biggest European research hub in the field and one of the most visited cities in Europe, Munich is without a doubt the perfect city to host ICLE 2025.

ICLE 2025 Is Organized in Partnership With

211203_Logo

Don't miss a thing!

Subscribe to our newsletter and be the first to know